Shares ofUltragenyx Pharmaceutical Inc.(NASDAQ:RARE) fell sharply during Monday's session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.

Ultragenyx Pharmaceutical shares dipped 9.4% to $42.46 on Monday.

Here are some other stocks moving in today's mid-day session.

Gainers

• Soligenix, Inc.(NASDAQ:SNGX) shares surged 71.5% to $0.6679 after the company announced that it was granted orphan drug designation to the active ingredient in MarVax for the prevention and post-exposure prophylaxis against MARV infection by the FDA.
• Longeveron Inc. (NASDAQ:LGVN) surged...